Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Deferred Taxes (2024 - 2026)

Cytek Biosciences posted quarterly Deferred Taxes of -$183000.0 for Q1 2026, up 45.54% year-on-year from -$125742.3 in Q1 2025, and down 100.47% on a QoQ basis from $38.6 million in Q4 2025.

Cytek Biosciences (CTKB) has 3 years of Deferred Taxes data on file, last reported at -$183000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Deferred Taxes rose 45.54% year-over-year to -$183000.0; the trailing twelve-month figure through Mar 2026 stood at $33.7 million (up 1146.24% YoY), and the FY2025 full-year result was $33.6 million, up 1262.75% from the prior year.
  • Deferred Taxes for Q1 2026 stood at -$183000.0, down from $38.6 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $38.6 million in Q4 2025 and bottomed at -$2.9 million in Q4 2024.
  • The 3-year median for Deferred Taxes is -$1.2 million (2025), against an average of $5.1 million.
  • The widest annual swing landed in 2025, when Deferred Taxes surged 1436.66%; it then surged 45.54% in 2026.
  • A 3-year view of Deferred Taxes shows it stood at -$2.9 million in 2024, then soared by 1436.66% to $38.6 million in 2025, then plunged by 100.47% to -$183000.0 in 2026.
  • The last three Deferred Taxes figures came in at -$183000.0 (Q1 2026), $38.6 million (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Deferred Taxes (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -33.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -101.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -351.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -9.40 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 300,000.00
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -16.70 Mn
10 Cytek Biosciences - - 21.25 Mn -183,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -183,000.00
Dec 31, 2025 38.58 Mn
Sep 30, 2025 -2.63 Mn
Jun 30, 2025 -2.06 Mn
Mar 31, 2025 -336,000.00
Dec 31, 2024 -2.89 Mn